7 February 2019 in Frontiers in Bioengineering and Biotechnology
The majority of human gut microbiome is comprised of obligate anaerobic bacteria that exert essential metabolic functions in the human colon. These anaerobic gut bacteria constantly crosstalk with the colonic epithelium in a mucosal anoxic-oxic interface (AOI). However, in vitro recreation of the metabolically mismatched colonic AOI has been technically challenging. Furthermore, stable co-culture of the obligate anaerobic commensal microbiome and epithelial cells in a mechanically dynamic condition is essential for demonstrating the host-gut microbiome crosstalk. Here, we developed an anoxic-oxic interface-on-a-chip (AOI Chip) by leveraging a modified human gut-on-a-chip to demonstrate a controlled oxygen gradient in the lumen-capillary transepithelial interface by flowing anoxic and oxic culture medium at various physiological milieus. Computational simulation and experimental results revealed that the presence of the epithelial cell layer and the flow-dependent conditioning in the lumen microchannel is necessary and sufficient to create the steady-state vertical oxygen gradient in the AOI Chip. We confirmed that the created AOI does not compromise the viability, barrier function, mucin production, and the expression and localization of tight junction proteins in the 3D intestinal epithelial layer. Two obligate anaerobic commensal gut microbiome, Bifidobacterium adolescentis and Eubacterium hallii, that exert metabolic cross-feeding in vivo, were independently co-cultured with epithelial cells in the AOI Chip for up to a week without compromising any cell viability. Our new protocol for creating an AOI in a microfluidic gut-on-a-chip may enable to demonstrate the key physiological interactions of obligate anaerobic gut microbiome with the host cells associated with intestinal metabolism, homeostasis, and immune regulation.
13 March 2024 in Skin Research and Technology
15 June 2022 in Cancer Research
Immune checkpoint inhibitors (ICI) targeting PD-1, PD-L1, or CTLA-4 have shown remarkable therapeutic outcomes in various cancers. However, the therapeutic efficacy of ICI-based immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) has been extremely limited. Recent studies strikingly revealed that the human gut microbiome controls the efficacy of immune checkpoint blockades. Yet, the effect of the gut microbiome on reinforcing the ICI efficacy in MSS tumors in CRC is unknown. Here, we suggest a microengineered CRC Chip that recapitulates the tumor microenvironment of individual CRC patients by introducing biopsy-derived colonic organoid epithelium. We have built a three-dimensional (3D) lumen-capillary interface under peristalsis-like motions and flow in an oxygen-controlled microenvironment. We leverage this pathomimetic CRC Chip to recapitulate the patient-specific tumor-microbiome-immune axis to demonstrate microbial immunomodulation on the tumor cells and cytotoxic tumor immunity. We co-cultured various human intestinal bacteria in a CRC Chip to assess the immunomodulatory contribution to the tumor epithelium. We found that living Bifidobacterium sp. significantly reduces the PD-L1 on the tumor surface, followed by elevated anti-tumor activity after CD8 T cell-mediated cytotoxic interactions. We envision that our CRC Chip model can potentially reduce the knowledge gap between the bench and bedside. Furthermore, our innovative CRC Chip model may potentially offer a platform to validate the “Druggable microbiome” and the utility of the patient’s avatar model for Precision Medicine. Citation Format: Yong Cheol Shin, Alexander Wu, Soyoun Min, Daesung Kim, Woojung Shin, S. Gail Eckhardt, R. Y. Declan Fleming, Hyun Jung Kim. Microbial immunomodulation for enhancing immunotherapeutic efficacy in a patient-specific colorectal cancer chip [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3862.